ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Sartor Discusses PSA Testing for Prostate Cancer

Oliver Sartor, MD
Published: Monday, Mar 17, 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.

Sartor says PSA testing is becoming increasingly controversial. Different guidelines call for different strategies, creating a lack of consistency in the field. In the early 1990s, all patients’ PSA levels were tested but today physicians understand that there are both risks and benefits to screening.

Sartor says PSA testing has the ability to save lives but there is an overdiagnosis and overtreatment of early stage prostate cancers due to PSA testing. All cancers that are found early do not necessarily need to be treated, as some are not clinically relevant. Physicians should only treat patients whose cancer needs to be treated, Sartor says.

<<< View more from the 7th Annual Interdisciplinary Prostate Cancer Congress

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.

Sartor says PSA testing is becoming increasingly controversial. Different guidelines call for different strategies, creating a lack of consistency in the field. In the early 1990s, all patients’ PSA levels were tested but today physicians understand that there are both risks and benefits to screening.

Sartor says PSA testing has the ability to save lives but there is an overdiagnosis and overtreatment of early stage prostate cancers due to PSA testing. All cancers that are found early do not necessarily need to be treated, as some are not clinically relevant. Physicians should only treat patients whose cancer needs to be treated, Sartor says.

<<< View more from the 7th Annual Interdisciplinary Prostate Cancer Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x